Antibe Therapeutics Future Growth
Future criteria checks 0/6
Antibe Therapeutics is forecast to grow earnings and revenue by 27.2% and 72.8% per annum respectively while EPS is expected to grow by 24.6% per annum.
Key information
27.2%
Earnings growth rate
24.6%
EPS growth rate
Pharmaceuticals earnings growth | 57.2% |
Revenue growth rate | 72.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?
Dec 15We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully
Mar 20Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business
Oct 16Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook
Feb 11We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate
Jan 07Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)
Jul 31Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021
Jul 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | N/A | -25 | N/A | N/A | 2 |
3/31/2026 | N/A | -24 | N/A | N/A | 2 |
3/31/2025 | N/A | -15 | N/A | N/A | 2 |
3/31/2024 | N/A | -20 | N/A | N/A | 3 |
12/31/2023 | N/A | -18 | -18 | -18 | N/A |
9/30/2023 | N/A | -18 | -18 | -18 | N/A |
6/30/2023 | N/A | -19 | -16 | -16 | N/A |
3/31/2023 | N/A | -19 | -16 | -16 | N/A |
12/31/2022 | N/A | -21 | -17 | -17 | N/A |
9/30/2022 | N/A | -22 | -15 | -15 | N/A |
6/30/2022 | N/A | -24 | -17 | -17 | N/A |
3/31/2022 | N/A | -25 | -17 | -17 | N/A |
12/31/2021 | N/A | -26 | 6 | 6 | N/A |
9/30/2021 | N/A | -26 | 1 | 1 | N/A |
6/30/2021 | -1 | -25 | -1 | -1 | N/A |
3/31/2021 | N/A | -24 | 0 | 0 | N/A |
12/31/2020 | 2 | -25 | -22 | -22 | N/A |
9/30/2020 | 5 | -23 | -18 | -18 | N/A |
6/30/2020 | 8 | -21 | -13 | -13 | N/A |
3/31/2020 | 10 | -19 | -11 | -11 | N/A |
12/31/2019 | 10 | -17 | -9 | -9 | N/A |
9/30/2019 | 10 | -16 | -8 | -8 | N/A |
6/30/2019 | 10 | -13 | -7 | -7 | N/A |
3/31/2019 | 10 | -13 | -7 | -7 | N/A |
12/31/2018 | 9 | -11 | -8 | -8 | N/A |
9/30/2018 | 9 | -9 | -8 | -8 | N/A |
6/30/2018 | 9 | -8 | -7 | -7 | N/A |
3/31/2018 | 9 | -7 | -7 | -6 | N/A |
12/31/2017 | 9 | -7 | -6 | -6 | N/A |
9/30/2017 | 8 | -7 | N/A | -5 | N/A |
6/30/2017 | 9 | -6 | N/A | -4 | N/A |
3/31/2017 | 9 | -6 | N/A | -3 | N/A |
12/31/2016 | 9 | -5 | N/A | -3 | N/A |
9/30/2016 | 9 | -4 | N/A | -3 | N/A |
6/30/2016 | 7 | -4 | N/A | -3 | N/A |
3/31/2016 | 4 | -3 | N/A | -3 | N/A |
12/31/2015 | 2 | -3 | N/A | -2 | N/A |
9/30/2015 | N/A | -3 | N/A | -2 | N/A |
6/30/2015 | 0 | -3 | N/A | -3 | N/A |
3/31/2015 | N/A | -4 | N/A | -4 | N/A |
12/31/2014 | N/A | -5 | N/A | -5 | N/A |
9/30/2014 | N/A | -5 | N/A | -4 | N/A |
6/30/2014 | N/A | -4 | N/A | -4 | N/A |
3/31/2014 | N/A | -3 | N/A | -3 | N/A |
12/31/2013 | N/A | -2 | N/A | -2 | N/A |
9/30/2013 | N/A | -1 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATE is forecast to have no revenue next year.
High Growth Revenue: ATE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATE's Return on Equity is forecast to be high in 3 years time